Literature DB >> 30667165

Comparison between gallium-68 citrate positron emission tomography-computed tomography and gallium-67 citrate scintigraphy for infection imaging.

Tatiana Segard1, Laurence M J A Morandeau2, Marina L Dunne1,3, James O Robinson4,5, Ronan J Murray6, Elizabeth A Geelhoed7, Roslyn J Francis1,8.   

Abstract

BACKGROUND: Preliminary studies have reported promising results for the utility of gallium-68 (Ga-68) citrate positron emission tomography-computed tomography (PET-CT) for infection imaging. This technique offers reduced radiation dose to patients, shorter time between injection and imaging and reduced time for image acquisition compared to the 'gold standard' nuclear imaging technique: gallium-67 (Ga-67) citrate scintigraphy. AIMS: To compare the two imaging modalities to ascertain whether Ga-68 citrate PET-CT is of equivalent diagnostic efficacy for bone and joint infection or pyrexia of unknown origin (PUO) and to assess image quality and reporter confidence.
METHODS: Patients with PUO and suspected bone or joint infection underwent Ga-67 citrate scintigraphy and Ga-68 citrate PET-CT. Participants were followed up for 3 months to record subsequent treatment, investigations and outcome.
RESULTS: 60 patients were recruited to this multicentre prospective study: 32 for bone and joint infection, 28 for PUO. The results show a sensitivity of 81% for Ga-67 citrate scintigraphy and 69% for Ga-68 citrate PET-CT, a specificity of 79% for Ga-67 citrate and 67% for Ga-68 citrate and were concordant for 76% of the participants. The reporting physician confidence was significantly lower for Ga-68 citrate (P < 0.05), frequently due to prominent physiologic blood pool activity adjacent to the site of infection.
CONCLUSION: The sensitivity and specificity of Ga-68 citrate PET-CT were found to be consistently lower than Ga-67 citrate scintigraphy. Additionally, due to the insufficient level of confidence of the reporting physicians for the Ga-68 citrate PET-CT, this modality could not currently be recommended to replace Ga-67 citrate scintigraphy for routine clinical use.
© 2019 Royal Australasian College of Physicians.

Entities:  

Keywords:  Ga-67 citrate; Ga-68 citrate; PET-CT; fever of unknown origin, infection

Mesh:

Substances:

Year:  2019        PMID: 30667165     DOI: 10.1111/imj.14231

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  6 in total

1.  Sensing Living Bacteria in Vivo Using d-Alanine-Derived 11C Radiotracers.

Authors:  Matthew F L Parker; Justin M Luu; Brailee Schulte; Tony L Huynh; Megan N Stewart; Renuka Sriram; Michelle A Yu; Salma Jivan; Peter J Turnbaugh; Robert R Flavell; Oren S Rosenberg; Michael A Ohliger; David M Wilson
Journal:  ACS Cent Sci       Date:  2020-02-04       Impact factor: 14.553

2.  Fully Automated Macro- and Microfluidic Production of [68Ga]Ga-Citrate on mAIO® and iMiDEVTM Modules.

Authors:  Olga Ovdiichuk; Emilie Roeder; Sébastien Billotte; Nicolas Veran; Charlotte Collet
Journal:  Molecules       Date:  2022-02-01       Impact factor: 4.411

Review 3.  Clinical Translation of Neutrophil Imaging and Its Role in Cancer.

Authors:  Doreen Lau; Laura M Lechermann; Ferdia A Gallagher
Journal:  Mol Imaging Biol       Date:  2021-10-12       Impact factor: 3.488

Review 4.  Nuclear Imaging of Bacterial Infection: The State of the Art and Future Directions.

Authors:  Ilona Polvoy; Robert R Flavell; Oren S Rosenberg; Michael A Ohliger; David M Wilson
Journal:  J Nucl Med       Date:  2020-08-06       Impact factor: 11.082

5.  Does gallium-citrate have yet another story to tell? Lessons relevant to the COVID-19 era.

Authors:  Lionel S Zuckier; Ana Y Valdivia; Edgar Zamora
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08       Impact factor: 9.236

6.  Radiolabeled Cationic Peptides for Targeted Imaging of Infection.

Authors:  Tolulope A Aweda; Zumrut F B Muftuler; Adriana V F Massicano; Dhruval Gadhia; Kelly A McCarthy; Stacy Queern; Anupam Bandyopadhyay; Jianmin Gao; Suzanne E Lapi
Journal:  Contrast Media Mol Imaging       Date:  2019-10-29       Impact factor: 3.161

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.